HomeCompareSURF vs EPRT

SURF vs EPRT: Dividend Comparison 2026

SURF yields 186.92% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SURF wins by $81.07M in total portfolio value
10 years
SURF
SURF
● Live price
186.92%
Share price
$1.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$81.13M
Annual income
$39,529,983.12
Full SURF calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — SURF vs EPRT

📍 SURF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSURFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SURF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SURF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SURF
Annual income on $10K today (after 15% tax)
$15,887.85/yr
After 10yr DRIP, annual income (after tax)
$33,600,485.65/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, SURF beats the other by $33,589,571.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SURF + EPRT for your $10,000?

SURF: 50%EPRT: 50%
100% EPRT50/50100% SURF
Portfolio after 10yr
$40.60M
Annual income
$19,771,411.92/yr
Blended yield
48.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

SURF
Analyst Ratings
4
Buy
3
Hold
Consensus: Buy
Altman Z
-6.6
Piotroski
3/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SURF buys
0
EPRT buys
0
No recent congressional trades found for SURF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSURFEPRT
Forward yield186.92%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$81.13M$63.4K
Annual income after 10y$39,529,983.12$12,840.73
Total dividends collected$76.16M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: SURF vs EPRT ($10,000, DRIP)

YearSURF PortfolioSURF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$29,392$18,691.59$11,205$505.18+$18.2KSURF
2$82,793$51,343.50$12,672$682.46+$70.1KSURF
3$223,755$135,166.69$14,490$930.48+$209.3KSURF
4$580,820$341,402.73$16,786$1,282.69+$564.0KSURF
5$1,449,711$828,233.59$19,753$1,791.56+$1.43MSURF
6$3,483,199$1,932,007.62$23,677$2,541.64+$3.46MSURF
7$8,065,345$4,338,322.11$29,008$3,672.99+$8.04MSURF
8$18,018,127$9,388,208.03$36,463$5,425.08+$17.98MSURF
9$38,880,730$19,601,334.30$47,238$8,221.57+$38.83MSURF
10$81,132,364$39,529,983.12$63,385$12,840.73+$81.07MSURF

SURF vs EPRT: Complete Analysis 2026

SURFStock

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Full SURF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this SURF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SURF vs SCHDSURF vs JEPISURF vs OSURF vs KOSURF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.